Zhejiang Doer Biologics Completes Phase 1b/2a Trial Enrollment for DR10624 in Obese Subjects with Hypertriglyceridemia

HANGZHOU, China, July 5, 2024 -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a biopharmaceutical company that focuses on developing innovative treatments for metabolic diseases and cancers, has announced the completion of patient enrollment for their Phase 1b/2a trial of DR10624 in New Zealand. This trial targets obese individuals with modest hypertriglyceridemia and aims to evaluate the efficacy of DR10624, a first-in-class, long-acting tri-specific agonist.

DR10624 targets the Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR). The novel treatment is being tested in a randomized, placebo-controlled, double-blind study to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in obese adults with a Body Mass Index (BMI) ranging from 30 to 45 kg/m2. Participants had fasting triglyceride levels of 150 mg/dL to 500 mg/dL at screening.

The study involves four different dosage levels of DR10624, administered via subcutaneous injection once a week for a period of 12 weeks. A 10:2 ratio is used to assign participants to receive either the treatment or a placebo. The study will also measure the effects of DR10624 on serum lipid levels, liver fat content, and body weight changes.

Yanshan Huang, Ph.D., the founder and Chief Executive Officer of Doer Bio, explained that DR10624 is an innovative biotherapeutic designed using the company’s MultipleBody® platform technology. This technology aims to achieve balanced activity across various metabolic diseases. Preclinical studies have indicated that DR10624 is highly effective in reducing body weight, normalizing blood lipid levels, and improving liver function.

"We're thrilled to announce the successful completion of patient enrollment for our Phase 1b/2a clinical trial of DR10624 in New Zealand. This is a significant milestone in our global clinical development efforts for DR10624," said Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio. He emphasized the growing need for effective treatments for obesity and hypertriglyceridemia and expressed optimism about DR10624’s potential to address these medical challenges. The company expects to report the trial results in early 2025.

Doer Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing multi-specific biotherapeutics, addressing unmet medical needs in metabolic diseases and cancers. The company has developed several proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!